Navamedic ASA (OSL:NAVA)

Market Cap	474.83M +34.4%
Revenue (ttm)	571.24M +6.4%
Net Income	-16.20M
EPS	-0.79
Shares Out	23.98M
PE Ratio	n/a
Forward PE	93.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,119
Average Volume	13,355
Open	19.55
Previous Close	20.30
Day's Range	19.25 - 19.90
52-Week Range	18.50 - 27.90
Beta	0.23
RSI	45.25
Earnings Date	Aug 14, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 38
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2025, Navamedic ASA's revenue was 565.36 million, an increase of 6.38% compared to the previous year's 531.44 million. Losses were -23.54 million, 329.1% more than in 2024.